While pre-treatment with aspirin and a P2Y12 inhibitor may be considered, it carries a class IIb recommendation in the 2023 ESC guidelines for acute coronary syndromes due to limited supporting evidence.2 Alternative options would lead to diagnostic delays or inappropriate management. The gene discussed is P2RY12; the disease is acute coronary syndrome.